Early Access — free while we kick the tires
EdgarHawk

RAPP Rapport Therapeutics, Inc. Insider Trading

Latest: Insider Sold $11.1M of Shares · May 2026
2 filings analyzed · Latest 2026-05-13
Insider buys
0
Insider sells
2
Unique insiders
1
Direction
Net selling
May 2026
2026-05-13
low
Third Rock Ventures V, LP Sell
133,618 shares
$5,377,323
@ $40.24
Significance 3/10

10% owner Third Rock Ventures V sells 133,618 shares for $5.4M; 4th sale at RAPP in 36 months with consistent prior exits well-timed as stock fell after each.

Third Rock Ventures V, a significant 10% beneficial owner, is shedding shares for the fourth time in the past three years—a pattern of repeated exits rather than accumulation. This latest sale occurred at a modest premium to the stock's recent trading range, and the fund's prior three exits at RAPP all proved well-timed, with the stock declining following each one, suggesting disciplined capital allocation. Rapport itself remains unprofitable with mounting quarterly losses, and while the stock has rallied notably in recent months, it still trades below its 52-week high. The fund's consistent exits here—now representing a reduction of over 2% of Third Rock Ventures V's original stake—underscore an institutional perspective: rebalancing a holding in a loss-making biotech rather than conviction-level accumulation typical of insider buyers betting on turnaround momentum.

2026-05-11
low
L.P. Third Rock Ventures V Sell
276,513 shares
$11,094,906
@ $40.12
Significance 3/10

Third Rock Ventures V (10% owner) sells 276k shares for $11.1M; first exit since well-timed prior sale, but stock up significantly in recent months.

L.P. Third Rock Ventures V, a significant institutional holder with over 10% ownership, divested a modest 4.1% of its stake across two sales in early May. The fund's prior sale at this company was well-timed—shares declined afterward—setting a positive precedent for exit decisions. However, this current sale arrives after the stock has gained substantially over recent months and still trades below its 52-week high, an environment where exits traditionally signal less urgency. The company remains unprofitable with mounting losses, though it generated meaningful quarterly revenue, creating a mixed fundamental backdrop. For a portfolio manager of this scale, modest portfolio rebalancing is routine, though the timing—after significant recent gains—suggests a pragmatic trim rather than alarm about deteriorating fundamentals or imminent business deterioration.

More Chemicals and Allied Products companies

Get alerts for RAPP

Add RAPP to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access